Lead Product(s): Trichomylin
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 27, 2021
Under the agreement, ZYUS’ cannabinoid formulations are expected to hit the Portuguese market as early as the second half of 2021. It's lead drug product candidate, Trichomylin® for pain management in a limited number of patients with osteoarthritis.